ATNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
180 Life Sciences's Accounts Payable for the quarter that ended in Mar. 2024 was $1.78 Mil.
180 Life Sciences's quarterly Accounts Payable increased from Sep. 2023 ($1.71 Mil) to Dec. 2023 ($1.89 Mil) but then declined from Dec. 2023 ($1.89 Mil) to Mar. 2024 ($1.78 Mil).
180 Life Sciences's annual Accounts Payable increased from Dec. 2021 ($0.59 Mil) to Dec. 2022 ($1.80 Mil) and increased from Dec. 2022 ($1.80 Mil) to Dec. 2023 ($1.89 Mil).
The historical data trend for 180 Life Sciences's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
180 Life Sciences Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Accounts Payable | 4.10 | 8.53 | 0.59 | 1.80 | 1.89 |
180 Life Sciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Accounts Payable | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1.21 | 0.84 | 1.71 | 1.89 | 1.78 |
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Thank you for viewing the detailed overview of 180 Life Sciences's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
James N. Woody | director, officer: Chief Executive Officer | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Marc Feldmann | director | 5 DURHAM TERRACE, LONDON X0 W25PB |
Lawrence Steinman | director | 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121 |
Mcgovern Jr. Donald A. | director | C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606 |
Quan Anh Vu | officer: COO / Chief Business Officer | 22616 ERWIN STREET, WOODLAND HILLS CA 91367 |
Ozan Pamir | officer: Interim CFO | 2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115 |
Pamela G Marrone | director | C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618 |
Teresa Deluca | director | 40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215 |
Russell T Ray | director | 2525 DUPONT DR, IRVINE CA 92612 |
Knuettel Ii Francis | director | 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701 |
Marlene Krauss | director, 10 percent owner, officer: Chief Executive Officer | C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022 |
Lawrence Marshall Gold | director | 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025 |
Jonathan B. Rothbard | officer: Chief Scientific Officer | 501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105 |
Shoshana Shendelman | director | C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
Richard W Barker | director | 290 COMMONWEALTH AVENUE #17, BOSTON MA 02115 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-05-2023
By Value_Insider Value_Insider • 12-16-2022
By Value_Insider Value_Insider • 11-21-2022
By GuruFocus Research GuruFocus Editor • 05-19-2023
By Stock market mentor Stock market mentor • 01-25-2023
By PurpleRose PurpleRose • 07-14-2022
By Stock market mentor Stock market mentor • 01-04-2023
By Stock market mentor Stock market mentor • 01-17-2023
By Value_Insider Value_Insider • 12-20-2022
By PurpleRose PurpleRose • 07-18-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.